mark4

MARK4 inhibitor 1 inhibits cancer cell proliferation, metastasis and induces apoptosis. MARK4 inhibitor 1 is a potent microtubule affinity-regulating kinase 4 (MARK4) inhibitor, with an IC50 of 1.54 μM.

MARK4 Inhibitor 2 is a potent inhibitor of Microtubule Affinity-Regulating Kinase 4 (MARK4), exhibiting a Kₘ of 6.3×10⁷ and an IC₅₀ of 0.82 μM. It effectively inhibits the growth of human cells, thereby offering potential for use in cancer research [1].

MARK4 inhibitor 4, with an IC50 value of 1.49 μM, serves as an agent targeting MARK4 for potential use in research related to cancer and tauopathies [1].

MAPK4 Inhibitor 3 (compound 23b) serves as a selective antagonist of MAPK4, demonstrating an inhibition constant (IC50) of 1.01 μM and effectively impeding the proliferation of cancer cells. This compound is utilized in research focused on cancer and tauopathies [1].

MRT199665 is an effective and ATP-competitive, selective MARK SIK AMPK inhibitor (IC50s of 2 2 3 2 nM, 10 10 nM, and 110 12 43 nM for MARK1 MARK2 MARK3 MARK14, AMPKα1 AMPKα2, and SIK1 SIK2 SIK3, respectively). MRT199665 suppresses the phosphorylation of S

PCC0208017 is an inhibitor of MARK3 and MARK4 with IC50s of 1.8 and 2.01 nM. PCC0208017 disrupts microtubule dynamics and displays potent antitumor activity.

FMF-06-098-1 is a multitargeted depressant that promotes the degradation of various kinases including AAK1, ABL2, AURKA, AURKB, BUB1B, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDK6, CDK7, CDK9, CHEK1, CSNK1D, EPHA1, PAK, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, SGK2, STK35, TNK2, UHMK1, ULK1, and WEE1 [1].